Lathosterol (Normalized) Test

Your standard cholesterol panel tells you how much cholesterol is circulating in your blood. What it cannot tell you is where that cholesterol came from. Some people carry high cholesterol because their intestines absorb too much from food. Others carry it because their liver is churning out more than it should. These two patterns respond to different treatments and carry different risks, but a routine lipid panel cannot distinguish between them.

Lathosterol is a molecule your liver produces as an intermediate step on the way to making cholesterol. When your liver ramps up cholesterol production, lathosterol levels rise in your blood. Measuring lathosterol and dividing by your total cholesterol gives a ratio that acts like a speedometer for your liver's cholesterol assembly line. A higher ratio means your body is making more cholesterol internally, regardless of what your LDL number says.

What This Ratio Actually Measures

Lathosterol sits near the end of the cholesterol production pathway in the liver. Because it is converted quickly into cholesterol and does not accumulate in large amounts on its own, the amount that escapes into your bloodstream is proportional to how fast your liver is running its cholesterol production machinery. Dividing by total cholesterol adjusts for the fact that people with more cholesterol in their blood naturally carry more of every cholesterol-related molecule, making the ratio a cleaner signal of production speed.

Validation studies have confirmed that this ratio tracks closely with direct measurements of whole-body cholesterol synthesis using specialized laboratory techniques. It is typically interpreted alongside companion markers of cholesterol absorption (plant sterols like campesterol and beta-sitosterol), which move in the opposite direction. When your synthesis markers are high, your absorption markers tend to be low, and vice versa. This pattern lets a clinician classify you as a "cholesterol synthesizer" or a "cholesterol absorber," a distinction that can shape which therapies work best for you.

Synthesizer vs. Absorber: Why It Matters for Treatment

In a randomized trial of 63 adults with mildly elevated cholesterol, people with a low lathosterol-to-cholesterol ratio (indicating low synthesis and relatively high absorption) had strong LDL cholesterol reductions when given plant sterols, which block absorption. People with a high ratio (high synthesizers) saw little benefit from the same treatment. Knowing your metabolic type before starting therapy could spare you months on an intervention unlikely to work for your biology.

This distinction also has implications for statin therapy. Statins work by blocking the enzyme that drives cholesterol synthesis in the liver. If your lathosterol ratio is already low, meaning your liver is not the main source of your cholesterol, a statin may be less effective than an absorption blocker like ezetimibe. In the HIJ-PROPER trial of 1,734 patients with acute coronary syndrome, a subgroup analysis found that adding ezetimibe to a statin showed greater benefit in patients whose sterol profiles indicated high cholesterol absorption rather than high synthesis.

Fatty Liver Disease

People with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD, or non-alcoholic fatty liver disease) consistently show elevated lathosterol levels, both in absolute terms and relative to total cholesterol. In a study of 124 MASLD patients and 43 healthy controls, lathosterol was significantly higher in the MASLD group and correlated independently with several non-invasive liver fat scores, including the fatty liver index and the triglyceride-glucose index.

This makes the lathosterol ratio a biochemical window into what is happening inside the liver. When the liver accumulates excess fat, its cholesterol production machinery revs up. This shift toward overproduction, detectable in a blood draw, can appear before liver enzymes become abnormal on a standard metabolic panel.

Familial Combined Hyperlipidemia

Familial combined hyperlipidemia (FCH) is one of the most common inherited lipid disorders, affecting roughly 1 in 100 people. In a study of 343 individuals from FCH families, both men and women with FCH had lathosterol levels about 51% higher than their unaffected relatives. This finding points to a fundamental difference in cholesterol production biology that runs in families and helps explain why some people have stubbornly high cholesterol despite diet changes.

Cardiovascular Risk: A Nuanced Picture

The relationship between lathosterol and heart disease is not a simple "higher is worse" story. In the AURORA trial, which followed 2,332 patients on long-term dialysis (a treatment that filters the blood when the kidneys have failed) for a median of 3.9 years, the group with the highest lathosterol-to-cholesterol ratio actually had about 19% lower cardiovascular death risk compared to the lowest group (a hazard ratio of 0.81). Meanwhile, higher levels of cholestanol (an absorption marker) predicted higher cardiovascular death risk in the same cohort.

This seems contradictory at first, but it makes sense once you stop thinking of lathosterol as a "good number / bad number" marker and start thinking of it as a metabolic fingerprint. In dialysis patients, a synthesis-dominant profile appears less dangerous than an absorption-dominant one. In the general population with metabolic syndrome, high synthesis (high lathosterol) often appears alongside obesity, insulin resistance, and fatty liver, conditions that carry their own cardiovascular consequences. The lathosterol ratio does not predict risk in isolation. It tells you which metabolic phenotype you belong to, and different phenotypes carry different risks in different clinical settings.

Research-Based Reference Values

There are no universally standardized clinical reference ranges for lathosterol normalized to total cholesterol. The values below come from published research studies using gas chromatography (a specialized lab technique that separates and measures individual sterol molecules) in specific populations. They are orientation, not targets. Your lab may report different numbers, possibly in different units, depending on the method used.

Compare your results within the same lab over time for the most meaningful trend. A single reading should be interpreted alongside your companion sterol markers (campesterol, beta-sitosterol, desmosterol), your standard lipid panel, and your clinical context.

When Results Can Be Misleading

Several factors can shift your lathosterol ratio without reflecting a true change in your cholesterol metabolism:

• Statin therapy: Statins can lower your lathosterol ratio by 40% to 70% within weeks because they directly suppress the enzyme that drives cholesterol synthesis. A low reading while on a statin reflects the drug working, not naturally low synthesis.
• Ezetimibe: This absorption blocker often causes a compensatory increase in lathosterol as your liver ramps up synthesis to offset reduced intestinal absorption. Again, this is a drug effect, not a worsening of your metabolism.
• Body weight changes: Rapid weight loss through very-low-calorie diets can drop lathosterol by about 0.39 μmol/mmol within weeks. If you are mid-diet when tested, your result will be lower than your usual baseline.
• Diurnal rhythm: Cholesterol synthesis follows a daily cycle, with production peaking overnight. Lathosterol and the related signaling molecule PCSK9 (proprotein convertase subtilisin/kexin type 9, a protein that regulates how quickly your body clears LDL cholesterol) show synchronized daily variation. Drawing blood at different times of day could produce modestly different results.